This is the first generic available for Revlimid in the United States.
Teva Pharmaceuticals launched lenalidomide, the first generic version of Celgene Corp.’s blockbuster cancer treatment Revlimid (lenalidomide capsules).
Revlimid, which treats multiple myeloma in combination with dexamethasone (Decadron, other brand names), myelodysplastic syndromes (specifically patients with a deletion of some part of chromosome 5), and mantle cell lymphoma, had annual sales of $2.3 billion as of 2021, according to IQVIA, Teva said in a news release.
Lenalidomide capsules will be available immediately in the United States in 5 mg, 10 mg, 15, mg, and 25 mg strengths. The drug also treats certain myelodysplastic syndromes.
“The launch of our first generic version of Revlimid in the United States provides patients with another important treatment option for these extremely challenging conditions, demonstrating Teva’s commitment to making complex generic drugs available to the patients who need them,” said Christine Baeder, senior vice president and chief operating officer of U.S. generics at Teva USA.
Lenalidomide adds to Teva’s generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, according to the company.
Additionally, Sandoz recently announced that it has launched a generic of lenalidomide in 19 countries across Europe.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More